Iron Deficiency Anemia vs Thalassemia Trait

Pathophysiology & Etiology

Results from depletion of total body iron stores limiting heme synthesis.
Progresses sequentially through iron depletion (low ferritin), iron-deficient erythropoiesis (low serum iron, high total iron-binding capacity), and overt anemia.
Erythropoiesis limited by lack of available iron; soluble transferrin receptor (sTfR) levels increase.
Primary etiologies include inadequate dietary intake (excessive cow milk), rapid growth demands (infancy, adolescence), and gastrointestinal or menstrual blood loss.

Autosomal recessive hemoglobinopathy causing impaired globin chain synthesis.
Beta-thalassemia trait: Pathogenic variants in one beta-globin gene reduce beta-chain production, creating relative alpha-chain excess.
Alpha-thalassemia trait: Deletion of two alpha-globin genes reduces alpha-chain production.
Chain imbalance causes unstable tetramers, mild ineffective erythropoiesis, and early destruction of red blood cells (RBCs).

IDA: Asymptomatic in mild stages; severe deficiency manifests with pallor, irritability, anorexia, fatigue, tachycardia, and pica.
Thalassemia Trait: Clinically asymptomatic; discovered incidentally on routine blood screening or family investigations.
Dietary Clues: IDA strongly correlates with excessive cow milk consumption or low-iron vegetarian diets.
Physical Examination: Thalassemia trait individuals maintain normal examinations without stigmata of thalassemia major (no massive hepatosplenomegaly or thalassemic facies).

Both conditions present as hypochromic, microcytic anemias.
Red Cell Count: Reduced in IDA; classically elevated in thalassemia trait.
Mean Corpuscular Volume (MCV): Very low (<80 fL) in both, but drop parallels hemoglobin decline in IDA.
Red Cell Distribution Width (RDW): Elevated (>14.5%) in IDA indicating significant anisocytosis; remains normal or mildly increased (<13%) in thalassemia trait.

IDA: Microcytosis, hypochromia, pronounced anisocytosis, poikilocytosis, and occasional teardrop cells.
Thalassemia Trait: Marked microcytosis and hypochromia without significant anisocytosis.
Target cells present in both; basophilic stippling strongly favors thalassemia trait.

Iron Profile: IDA characterized by low ferritin (<15 ng/mL), low serum iron, high total iron-binding capacity (TIBC), and transferrin saturation <16%. Thalassemia trait maintains normal or elevated iron stores.
Soluble Transferrin Receptor (sTfR): Elevated in IDA; useful for distinguishing IDA from other microcytic states.
Free Erythrocyte Protoporphyrin (FEP): Elevated in IDA; normal in thalassemia trait.
Hemoglobin Analysis (HPLC/Electrophoresis):
- Beta-Thalassemia Trait: Elevated HbA2 (>3.5%); HbF variably elevated in 50% of cases. Concomitant IDA artificially lowers HbA2, potentially masking the thalassemia diagnosis until iron stores are replete.
- Alpha-Thalassemia Trait: Normal hemoglobin analysis beyond the newborn period (where Hb Bart’s is 3-10%); definitive diagnosis requires genetic testing or exclusion.

Parameter	Iron Deficiency Anemia	Beta-Thalassemia Trait	Alpha-Thalassemia Trait
Clinical Symptoms	Mild to severe (fatigue, pica)	None	None
Hemoglobin	Low (<10 g/dL)	Mildly low (10-12 g/dL)	Normal to mildly low
MCV	Very low (<80 fL)	Low (<80 fL)	Low
RBC Count	Reduced	Elevated	Elevated
RDW	High (13-15%)	Normal or mildly increased	Normal
Peripheral Smear	Anisocytosis, poikilocytosis	Microcytosis, basophilic stippling	Microcytosis, hypochromia
Serum Iron	Low	Normal	Normal
Serum Ferritin	Low (<15 ng/mL)	Normal or high	Normal or high
TIBC	High	Normal	Normal
FEP	High	Normal	Normal
HbA2 (HPLC)	Normal or decreased	Increased (>3.5%)	Normal
HbF (HPLC)	Normal	Normal or increased	Normal

Identify and correct underlying etiology (dietary correction, gastrointestinal blood loss evaluation).
Initiate therapeutic trial of oral ferrous sulfate (3 mg/kg/day elemental iron).
Monitor reticulocytosis peak at 5-10 days, followed by hemoglobin rise (1 g/dL in 1 month).
Continue oral iron therapy for 4-6 months after anemia correction to replenish marrow iron stores.

Medical follow-up or iron therapy not required unless definitive concomitant iron deficiency is confirmed by ferritin levels.
Avoid inappropriate empiric iron supplementation to prevent iatrogenic iron toxicity.
Provide genetic counseling to screen adolescents and partners; prevents thalassemia major in subsequent offspring.
Offer prenatal testing (chorionic villus sampling at 10-12 weeks) if both partners are identified as thalassemia carriers.